Northview Lifesciences

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030. It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.

Renaissance BioScience Corp. is a biotechnology company headquartered in Vancouver, Canada, specializing in proprietary yeast-based technology solutions designed to address various industrial and health challenges. Founded in 2013, the company focuses on developing yeast strains that significantly reduce the formation of acrylamide in carbohydrate-rich foods and coffee, as well as hydrogen sulfide in alcoholic beverages such as wine, beer, and cider. Their products cater to the food and beverage sectors, providing sustainable ingredients that enhance quality and safety. Renaissance BioScience employs a combination of whole-organism and gene-targeted engineering to optimize yeast for diverse applications, contributing to improvements in food production, environmental sustainability, and health.

CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.

Precision Nanosystems develops tools and processes for the development and manufacture of nanoparticles for use as medicines and in medical research. It offers NanoAssemblr benchtop instrument for prototyping of nanoparticles, as well as for the development of nanoparticle-based drugs delivering RNA, small-molecule, and protein therapeutics. The company also provides Neuro9Kit for the study of gene function in neurons and glial cells, as well as potent delivery to primary cells; Test9Kit for the study of gene function in various cell types; and Hepato9Kit for the study of gene function in the liver. In addition, it provides instruments, reagents, and services to the life sciences researchers.

Perimeter Medical Imaging is a privately held medical device company with offices in Toronto, Canada. Our executive team of medical device leaders holds an excellent track record of successfully building companies and improving outcomes for clinicians and patients.

Synaptive Medical Inc. is a medical device manufacturing company based in Toronto, Canada, that focuses on neurosurgery, medical imaging, and surgical navigation. Founded in 2012, the company develops integrated systems and solutions aimed at improving patient care and outcomes both in and beyond the operating room. Its product offerings include BrightMatter Prime for pre-operative planning, BrightMatter Servo for 3D navigation, and ImageDrive for patient data management across care settings. Additionally, Synaptive provides tools like BrightMatter Simulate for surgical training, BrightMatter Plan for tractography generation, and BrightMatter Guide for real-time surgical assistance. The company emphasizes collaboration with healthcare professionals, providing advanced imaging and data solutions tailored for neurosurgeons, radiologists, and healthcare facilities, all designed to enhance the quality of care and streamline clinical workflows.

AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, focused on developing innovative therapeutics for neurological disorders. The company's clinical pipeline includes several product candidates targeting epilepsy, such as XEN496 and XEN1101, both Kv7 potassium channel modulators currently in Phase II trials, and XEN901, a selective Nav1.6 sodium channel inhibitor in Phase I trials. Additionally, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase I trials. Xenon utilizes a proprietary discovery platform, known as Extreme Genetics, to identify genetic insights from families with severe phenotypes, enabling the development of novel medicines for both orphan and more common diseases. The company has established a collaboration with Neurocrine Biosciences to advance first-in-class treatments for epilepsy, highlighting its commitment to addressing unmet medical needs in the field of neurology.